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Opinion
Innovation and competition in advanced
therapy medicinal products
Enrique Seoane-Vazquez1 , Vaishali Shukla2 & Rosa Rodriguez-Monguio3
EMBO Mol Med (2019) e9992
A dvanced therapy medicinal products(ATMPs), including gene therapy,cell therapy, and tissue engineering
products, represent a paradigm shift in
health care as they have great potential for
preventing and treating many diseases (Food
and Drug Administration (FDA), 2013). By
way of example, only 367 (8.0%) of the
4,603 rare diseases and conditions listed by
the NIH Genetic and Rare Diseases Informa-
tion Center had at least one FDA-approved
drug therapy in early 2018. An estimated
3,038 (66.0%) of those rare diseases and
conditions are congenital and genetic
diseases that could potentially be treated by
gene therapy. There are already ATMPs
under development to address these and
many other unmet medical needs (FDA,
2013; MIT NEWDIGS FoCUS Project, 2017)
and for the treatment of prevalent condi-
tions, such as cardiovascular, neurologic,
and metabolic diseases.
However, the high cost of ATMPs has
given rise to concerns about the affordability
of these breakthrough therapies for health
care systems and patients. Furthermore, the
projected increase of ATMP approvals in the
upcoming decades will create a significant
financial challenge for patients, insurance
companies, and public health care schemes.
During the past decades, the rise of generic
markets for drugs and biologics has helped
to drive down the costs for many drugs and
other medicinal products; a similar market
for generic versions of ATMP could therefore
help to make these advanced treatments
more affordable. Yet, there are several
factors that may hinder a future competitive
market for ATMPs and thereby affordability.
ATMP authorizations and prices
In the USA and Europe, the regulation of
ATMPs falls under the biologic licensing
procedures of the FDA and the European
Medicines Agency (EMA), respectively. Both
agencies have implemented a regulatory
framework to expedite the development and
approval of ATMPs that address unmet
medical needs or provide new therapies for
serious or life-threatening diseases. Both
regulatory frameworks also enable the use
of technical requirements adapted to the
characteristics of each ATMP and explicitly
enable companies and other developers to
gain access to scientific and regulatory
advice from the respective agency. Medical
devices intended for use with a specific
ATMP may be evaluated either as part of the
ATMP or as stand-alone devices. There are
differences in the classification of ATMPs by
the FDA and the EMA. The FDA classifies
hematopoietic progenitor cell (HPC) cord
blood products as an AMTP. The EMA
considers that HPC cord blood products do
not fit the definition of AMTP because they
are not subject to substantial manipulation
and are intended to be used for the same
essential function in the recipient and the
donor.
As of December 31, 2018, the FDA had
authorized 16 ATMPs (11 cell therapies,
including eight HPC cord blood products;
four gene therapy products and one tissue
engineering product), and the EMA had
authorized 13 ATMPs (three cell therapies,
six gene therapy products, and four tissue
engineering products; Table 1). Six products
(autologous cultured chondrocytes on a
porcine collagen membrane-specific marker
proteins, axicabtagene ciloleucel, sipuleucel-
T, talimogene laherparepvec, tisagenlecleucel,
and voretigene neparvovec) were authorized
by both agencies. The FDA and EMA also
granted orphan designation to 4 and
8 ATMPs, respectively. These products
address several disease areas including
progenitor cell transplantation, cancer, and
cartilage defects. However, companies had
also withdrawn 4 ATMPs authorized by the
EMA from the market, citing commercial
reasons for discontinuing their availability.
The manufacturer price for an ATMP
treatment ranges from US$18,950 for a
tissue-engineered product to US$1,206,751
for a gene therapy (Table 1). On average,
prices are higher for gene therapy (US
$357,309–US$1,206,751) than for cell ther-
apy (US$110,920–US$814,780) and tissue-
engineered products (US$ $18,950–US
$93,432). Yet, these prices do not include
purchasing, inventory, and management costs
that may significantly increase the overall
treatment cost. By way of comparison, the
treatment cost for the four ATMPs approved
by both regulatory agencies was higher in
the USA than in Europe: tisagenlecleucel
costs 15.0% more in the United States
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Table 1. FDA and EMA ATMP market authorizations and prices.
Established name Manufacturer Agency
Authorization
date
Market
withdrawal
Price at
market
entry (US$) Price type
Gene therapy
Alipogene tiparvovec UniQure EMA 10/25/2012 10/28/2017 $1,206,751 Germany, Retail
Autologous CD34+ enriched
cell fraction that contains
CD34+ cells transduced
with retroviral vector that
encodes for the human
adenosine deaminase
(ADA) cDNA sequence from
human hematopoietic
stem/progenitor (CD34+)
cells
GlaxoSmithKline EMA 5/26/2016 Marketed $738,223 UK, Retail excludes VAT
Axicabtagene ciloleucel Gilead Sciences EMA 8/23/2018 Marketed NA
FDA 10/18/2017 Marketed $373,000 US, Wholesale
Acquisition Cost (WAC)
Talimogene laherparepvec Amgen EMA 12/16/2015 Marketed $357,309 Germany, Retail
FDA 10/27/2015 Marketed $466,077 US, WAC
Tisagenlecleucel Novartis EMA 8/22/2018 Marketed $441,538; $413,120 Germany, Retail; UK,
Proposed by company
FDA 8/30/2017 Marketed $475,000 US, WAC
Voretigene neparvovec Spark Therapeutics EMA 11/23/2018 Marketed NA
FDA 12/19/2017 Marketed $850,000 US, WAC
Tissue-engineered products
Characterized viable
autologous cartilage cells
expanded ex vivo
expressing specific marker
proteins
TiGenix EMA 11/16/2009 7/29/2016 $21,926 UK, Proposed
by company
Autologous cultured
chondrocytes on a porcine
collagen membrane-
specific marker proteins
Vericel EMA 6/27/2013 9/5/2014 $21,926 UK, Proposed
by company
FDA 12/13/2016 Marketed $38,179 US, WAC
Ex vivo expanded
autologous human corneal
epithelial cells containing
stem cells
Chiesi Farmaceutici EMA 2/17/2015 Marketed $93,432 UK, Retail excludes VAT
Spheroids of human
autologous matrix-
associated chondrocytes
Don AG EMA 7/10/2017 Marketed $18,950 UK, Proposed
by company
Cell therapy
Allogeneic cultured
keratinocytes and
fibroblasts in bovine
collagen
Organogenesis
Incorporated
FDA 3/9/2012 Marketed NA
Allogeneic T cells
genetically modified with a
retroviral vector encoding
for a truncated form of the
human low-affinity nerve
growth factor receptor
(DLNGFR) and the herpes
simplex I virus thymidine
kinase (HSV-TK Mut2)
MolMed Spa EMA 8/18/2016 Marketed $814,780 Germany, Retail
Azficel-T Fibrocell Technologies FDA 6/21/2011 Marketed NA
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than in Europe, sipuleucel-T 27.1%, talimo-
gene laherparepvec 30.4%, and autologous
cultured chondrocytes 74.1%.
One major factor for the high cost of
AMTPs is that these cater to only a small
number of patients—often qualifying for
orphan drug designation—and are used in
personalized medicine (FDA, 2013). For
example, the EMA authorized a gene ther-
apy using autologous CD34+ cells to cure
ADA-SCID, a rare disease that affects
between one in 200,000 and one in
1,000,000 children. This gene therapy is
administered at a single specialist center in
Italy. Other factors for the high prices of
ATMPs include the current intellectual prop-
erty regulation that limits competition and
reimbursement mechanisms. European
public health care systems and US payers
usually cover the costs for most ATMPs,
especially those without therapeutic alterna-
tives.
While high prices may incentivize ATMP
development, they limit accessibility and
could even lead to market discontinuations
for commercial reasons (Halioua-Haubold
et al, 2017). Market withdrawals are also
related with the high cost associated with
maintaining manufacturing capabilities,
patient registries and risk management proce-
dures, post-marketing studies, development
and validation of assays or regulatory
reassessments, and other regulatory inspec-
tions.
Market competition for generics
As ATMPs are costly for health insurance
schemes and patients, competition will be
essential for improving affordability and for
these products to become mainstream medi-
cine. The history of and experience with
generic drugs, biosimilar products, and
medical devices illustrates how increased
market competition has benefited medical
care during the past decades. In 1984, the
Waxman Hatch Act (WHA) enabled
the growth of the generic drug industry in
the USA and elsewhere by establishing an
abbreviated new drug application (ANDA)
process for the review and approval of
generic drugs. A generic drug company can
use the safety and efficacy data of the refer-
ence drug, typically the original new drug
application (NDA), to prepare an ANDA
without the need to replicate costly clinical
studies. Upon demonstration of chemical
and biological equivalence during the ANDA
review, the FDA determines the therapeutic
equivalence and interchangeability of the
generic drug. The WHA also created a
process for generic companies to challenge
the validity of brand drug patents and
allowed companies to use patented drugs to
prepare an ANDA. The ANDA process was
eventually adapted by regulatory agencies in
Europe and by the EMA at its inception in
1995.
The FDA and the EMA have also estab-
lished routes for the review and approval of
biosimilar alternatives to branded biologic
products. The process is more stringent
and costly than the process for generic
drugs, partially because it is not possible to
exactly replicate complex biologic products
and demonstrate bioequivalence. To get
approved, a biosimilar product must have
the same route of administration, dosage
form, and strength as the reference product.
Additionally, the application must demon-
strate that the product is highly similar to
the reference product based on data from
analytical, animal, and clinical studies. A
biosimilar product that meets these stan-
dards is considered interchangeable with the
reference biologic.
The generic and biosimilar markets are
examples of how market competition can
reduce prices, improve affordability, and
expand access to therapies. For example,
aripiprazole, an atypical antipsychotic, and
imatinib mesylate, an antineoplastic agent,
experienced important reductions in cost
after generic entry. In February 2018, two
and a half years after generic entry, the
community pharmacy National Average
Table 1 (continued)
Established name Manufacturer Agency
Authorization
date
Market
withdrawal
Price at
market
entry (US$) Price type
Darvadstrocel Takeda Pharma EMA 3/23/2018 Marketed NA
Hematopoietic progenitor
cell cord blood
Cleveland Cord Blood
Center
FDA 9/1/2016 Marketed NA
SSM Cardinal Glennon
Children’s Medical
Center
FDA 5/30/2013 Marketed NA
Bloodworks FDA 1/28/2016 Marketed NA
Clinimmune Labs,
University of Colorado
Cord Blood Bank
FDA 5/24/2012 Marketed NA
Duke University School
of Medicine
FDA 10/4/2012 Marketed NA
LifeSouth Community
Blood Centers
FDA 6/13/2013 Marketed NA
New York Blood Center FDA 11/10/2011 Marketed NA
MD Anderson Cord Blood
Bank
FDA 6/21/2018 Marketed NA
Sipuleucel-T Dendreon EMA 9/6/2013 5/6/2015 $110,920 Germany, Retail
FDA 4/29/2010 Marketed $141,005 US, WAC
ATMP, Advanced therapy medicinal product; EMA, European Medicines Agency; FDA, Food and Drug Administration.
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Drug Acquisition Cost (NADAC) collected by
the Centers for Medicare and Medicaid
Services for 30 day supply of aripiprazole
10MG tablet was 78 times lower for the
generic than for the brand version of
the drug ($11 and $857, respectively). In the
case of imatinib mesylate tablet 400MG, the
30-day supply NDAC price was 18.5 times
lower for the generic than for the brand
($529 vs. $9,808) version of the drug in
October 2018, two and a half years after
generic entry. Savings associated with the
use of biosimilars can also be substantial. In
October 2018, the manufacturer average
sales price reported by CMS for a day of
treatment of filgrastim (leukocyte growth
factor) was 43% lower for the biosimilar
than the reference biologic product ($203 vs.
$355, respectively).
The acceptance of low-cost alternative
generics and biosimilar products has been
facilitated by significant savings. In 2016,
generic drugs represented 90% of the
prescriptions and 26% of the drug expendi-
tures in the USA (IQVIA Institute for Human
Data Science, 2017). Nevertheless, the
number of biosimilars authorized in the USA
remains limited. The FDA approved the first
biosimilar product (filgrastim, a recombi-
nant-DNA form of granulocyte colony-stimu-
lating factor used in cancer therapy) in
March 2015. In the fourth quarter of 2016,
two alternative products to filgrastim
captured 30% of the market (Mulcahy et al,
2017). By March 2018, the FDA had
approved nine biosimilar products for six
different biologics.
In the EU, the market share of generic
drugs varies by country from 11 to 81% of
the drug units and 6 to 36% of the expendi-
tures (OECD, 2017). The EMA approved the
first biosimilar (somatotropin) in April 2006;
by March 2018, the EMA had approved 39
biosimilar products corresponding to 15 dif-
ferent biologic products. The EU market
share of biosimilars as a percent of sales also
varies by product. For example, biosimilar
market sales represented 4% of the refer-
ence insulins and 88% of granulocyte
colony-stimulating factors in 2016 (Quin-
tilesIMS, 2017).
In the case of medical devices, premarket
approval applies to devices that support or
sustain human life, are of significant impor-
tance in preventing impairment of human
health, or present a potential, unreasonable
risk of illness or injury. Competition is
limited for devices that are subject to
premarket authorization processes. The pre-
approval process requires valid scientific
evidence that the device is safe and effective
for its intended use and may require clinical
trials. A device can be exempted from
premarket regulatory requirements if it is
considered safe, effective, and substantially
equivalent to a legally marketed device and
enters the market after notification to the
regulatory organizations (FDA in the USA
and notified bodies in the EU). Overall, the
bioequivalence of generic drugs (Carpenter
& Tobbell, 2011), the similarity of biosimi-
lars, and the substantial equivalence of
medical devices are the main factors allow-
ing for product interchangeability and there-
fore efficient market competition.
Demonstrating biosimilarity
for ATMPs
While the generics market for drugs, medical
devices, and some biologics has been driv-
ing down prices and improving affordability
and access to medicinal products, the chal-
lenge to establish a similar market of gener-
ics makers of ATMPs is considerably
greater. A first barrier would be the current
regulatory scheme itself. ATMP is a complex
and dynamic regulatory area compared with
the now well-established regulation of
drugs, biologics, and medical devices. Prod-
ucts classified under the ATMP umbrella can
be very diverse, and current regulations are
product-specific and focus on incentivizing
innovation. It would first require a stable
and well-defined ATMP regulatory frame-
work that sets reference standards and crite-
ria for approval, along with implementing
regulatory pathways for ATMP biosimilar
review and authorization. The demonstra-
tion of biosimilarity for ATMPs is also chal-
lenging because those products are often
complex active substances, patient-specific
(autologous), or require careful matching of
donor and recipient (allogeneic). Moreover,
only few validated biomarkers for establish-
ing biosimilarity have been identified. Regu-
latory systems must address the complexity
of ATMPs and the difficulty of comparing
outcomes and demonstrating biosimilarity of
highly individualized therapies to ensure
clinical equivalence.
The development of biosimilar ATMPs
will also depend on the cost and barriers to
access the innovator product, which is
required to perform comparative studies. In
addition, biosimilar ATMP clinical studies—
if required—will be challenging and costly
and face the same difficulties in enrolling
sufficient number of patients as the original
product. The success of a ATMP biosimilar
industry will also require the development
of technologies to enable large-scale, repro-
ducible, and cost-effective manufacturing
of high-quality products (Dwarshuis et al,
2017).
Lastly, while the current regulatory
framework for ATMPs focuses on providing
companies with incentives for innovation, it
is not necessarily supporting competition.
Aligning the necessary incentives for
research and development with health care
budgetary constraints is an important chal-
lenge for policymakers and regulatory agen-
cies (Rodriguez-Monguio et al, 2017). Yet,
the complexities of the regulatory frame-
work, clinical effectiveness, and safety,
along with the economic and ethical issues
of ATMP innovation, access, and affordabil-
ity, have not been sufficiently discussed so
far.
Conclusions
To date, only a few ATMPs have been
approved by FDA and EMA. However,
many more therapies are under preclini-
cal/clinical development and are expected
to reach the market in the foreseeable
future. The high cost of ATMP limits
affordability for public and private payers
and reduces patient access to treatment
for what are often life-threatening condi-
tions and diseases. Current regulatory and
policy initiatives focus on encouraging
innovation and expediting review of
ATMPs rather than on enabling market
competition and thereby ensuring
affordability and availability of these new
therapies. A greater market and ensuing
competition for ATMP biosimilars will be
limited by the complexity of ATMPs, fast
technological evolution, difficulties in
demonstrating clinical equivalence, the
high cost of development and manufactur-
ing, and the lack of a well-defined regulatory
framework for review and authorization of
biosimilar ATMPs.
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